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Abstract
Cyclosporin-A (CsA) is an immunosuppressant associated with acute kidney injury and chronic kidney disease. Nephrotoxicity
associated with CsA involves the increase in afferent and efferent arteriole resistance, decreased renal blood flow (RBF) and
glomerular filtration. The aim of this study was to evaluate the effect of Endothelin-1 (ET-1) receptor blockade with bosentan
(BOS) and macitentan (MAC) antagonists on altered renal function induced by CsA in normotensive and hypertensive animals.
Wistar and genetically hypertensive rats (SHR) were separated into control group, CsA group that received intraperitoneal
injections of CsA (40 mg/kg) for 15 days, CsA+BOS and CsA+MAC that received CsA and BOS (5 mg/kg) or MAC (25 mg/kg)
by gavage for 15 days. Plasma creatinine and urea, mean arterial pressure (MAP), RBF and renal vascular resistance (RVR),
and immunohistochemistry for ET-1 in the kidney cortex were measured. CsA decreased renal function, as shown by increased
creatinine and urea. There was a decrease in RBF and an increase in MAP and RVR in normotensive and hypertensive
animals. These effects were partially reversed by ET-1 antagonists, especially in SHR where increased ET-1 production was
observed in the kidney. Most MAC effects were similar to BOS, but BOS seemed to be better at reversing cyclosporine-induced
changes in renal function in hypertensive animals. The results of this work suggested the direct participation of ET-1 in renal
hemodynamics changes induced by cyclosporin in normotensive and hypertensive rats. The antagonists of ET-1 MAC and BOS
reversed part of these effects.
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Introduction
Cyclosporine-A (CsA) is an agent widely used in
transplants, such as kidney transplant (1). It is a cyclic,
lipophilic medicine, and has immunosuppressive activity
to T cells and other inflammatory cells. It binds to cyclo-
philin, its cytoplasmic receptor, and the CsA-cyclophilin
complex binds to calcineurin, a serine-threonine phos-
phatase that is calcium- and calmodulin-dependent, inhibit-
ing their ability to dephosphorylate nuclear factors present
in the cytosol (2,3) as nuclear factor T cells (NF-ATc). CsA
blocks NF-ATc and inhibits the transcription process,
preventing the production of these cytokines (4).
The adverse effects, such as nephrotoxicity, hepato-
toxicity, hypertension and risk of malignancy, are observed
in sub-acute and chronic treatment (5). Renal dysfunction
induced by CsA in humans is an independent risk factor
for graft loss and mortality after kidney transplantation,
and cardiovascular disease is the main cause of death
post-transplantation. CsA use has been described to be
associated with chronic kidney disease and end stage
renal disease. Diabetes mellitus and hypertension are
the main risk factors to renal disease leading to kidney
transplantation. It is reasonable to suggest that both
events can superimpose. In rats, the tubular atrophy
and irreversible interstitial fibrosis, initially compromis-
ing the medullary rays and after the renal cortex, are
observed (6).
The renal vascular injury induced by CsA involves
afferent arterioles and small arteries with resultant
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increase in renal vascular resistance, decrease in renal
blood flow and glomerular filtration (7). The arteriolar
vasoconstriction induced by cyclosporine-A is due to the
activation of the renin-angiotensin system (7–9). Attempts
to prevent acute toxicity with angiotensin converting enzyme
blockers or angiotensin receptors antagonists showed
conflicting results. Burdmann et al. (6), demonstrated that
it is possible to prevent interstitial fibrosis induced by
CsA with the use of losartan and enalapril. The decrease
in renal blood flow caused by chronic vasoconstriction
may be the stimulus for the fibrotic process in the renal
interstitial as well as for glomerular sclerosis. However,
chronic renal ischemia can also lead to interstitial fibro-
sis. Thus, the use of vasodilation agents can prevent or
reverse renal lesion induced by CsA.
Endothelin peptides are produced in various tissues,
and they act as modulators of vascular tone, cell pro-
liferation and hormone production (10). Endothelin-1 (ET-1)
is mainly related to endothelial dysfunction, but other
cells are also capable of producing the ET-1, such as
vascular smooth muscle cells and mesangial cells of the
kidney (11). Stimuli as ischemia, hypoxia or shear stress
of blood vessels induce the production and secretion of
ET-1 (10,11).
ET-1 exerts its function in the target cell via two
receptors, ETA and ETB (11). ETA receptor activation
is primarily responsible for vasoconstriction, cell pro-
liferation, proteinuria and the induction of renal fibrosis
induced by endothelin-1. Plasma and renal ET-1 levels
are elevated in diabetic patients and mediate diabetic
nephropathy. Differently, ETB receptor activation releases
vasodilating substances such as prostacyclin and nitric
oxide, leading to vasodilation first and then vasoconstric-
tion. These are present in greater quantities in endothelial
cells (10,11).
ET-1 can also be involved in the nephrotoxicity
induced by CsA. In vivo administration of high doses of
CsA in mice was associated with a significant increase in
the ET-1 production, increase in renal vascular resistance,
reduction of glomerular filtration and the development of
hypertension. In humans, the association between high
systemic levels of ET-1 with the administration of high
doses of CsA was observed, suggesting that this relation-
ship may also be observed clinically (10).
Several ET-1 antagonists were developed. Their
principal therapeutic use is the treatment of idiopathic
pulmonary fibrosis and pulmonary arterial hypertension,
reducing morbidity and mortality in patients with pulmo-
nary hypertension (12,13). However, the effect of ET-1
antagonists in renal blood flow or renal fibrosis induced
by the use of CsA in hypertensive animals was poorly
investigated.
The present study compared the effect of ET-1 antag-
onist bosentan and the new antagonist macitentan, also
called actelion-1 or ACT-064,922, in the nephrotoxicity
induced by CsA in hypertensive rats.
Material and Methods
Animal treatment
The experimental protocol was approved by the Ethics
Committee of the Universidade Cruzeiro do Sul, also in
agreement with the Brazilian guidelines for scientific animal
care and use (14,15).
Male Wistar rats and genetically hypertensive rats
(SHR), weighing 200–250 g, were divided into groups of
10 rats. The animals in the control group were maintained
under controlled conditions during the experimental
protocol. The CsA group received daily intraperitoneal
injections of CsA (Sigma, USA), 40 mg/kg, during the
last 15 days. The rats in the CsA and bosentan group
(CsA+BOS) were treated with intraperitoneal injections of
CsA (40 mg/kg) as well as daily intraperitoneal injections
of bosentan (5 mg/kg). The CsA and macitentan group
(CsA+MAC) was treated with intraperitoneal injections
of CsA (40 mg/kg) as well as daily macitentan (25 mg/kg)
administration by gavage.
The animals were allowed free access to tap water
and low sodium food initiated 3 days before and during
the experimental protocol. The low sodium diet composed
of carbohydrate, vitamins and amino acids supplement
(Aminomix, Vetnil, Brazil) was used to potentiate the nephro-
toxic effect of CsA, according to Burdmann et al. (6).
At 0 (basal) and 15 days (post-treatment) after the begin-
ning of experimental protocols, blood samples were
collected from the lateral tail vein, and the animals were
maintained in metabolic cages over 24 h for urine col-
lection. In some experiments, the urine volume after at
least 3 days of hyposodic diet (post-diet) was collected
and quantified. The animals were killed 15 days after the
beginning of the experimental protocol, and both the right
and left kidneys were removed for immunohistochemistry
analysis. Biochemical parameters in the plasma and urine
samples were determined.
Biochemical analysis
The levels of blood creatinine and blood urea were
assayed spectrophotometrically according to standard pro-
cedures by using commercially available diagnostic kits
(Labtest Diagnostica, Brazil). Creatinine was determined
by a colorimetric method based on the Jaffé reaction (16)
and the creatinine clearance was assessed. Urea was
determined using a colorimetric assay based on urease
activity (17). Levels of creatinine and urea are reported in
mg/dL. Urine sodium concentrations in urine were deter-
mined with a Micronal B462 flame photometer (Brazil).
Sodium excretion are reported as percentage of the basal
sodium excretion.
Kidney hemodynamics
On the last day of the experimental protocol, 10 animals
per group were anesthetized with ketamine (100 mg/kg)
and xylazine (10 mg/kg) intraperitoneal injections
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(Agribands, Brazil) for measurement of renal blood flow
(RBF). The left renal artery was isolated and surrounded
by an ultrasonic flowmeter probe (T402, Transonic Sys-
tems Inc., USA) to measure blood vessel flow. Mean
arterial blood pressure (MAP) was recorded via catheter-
ization of the femoral artery and renal vascular resistance
(RVR) was calculated by the following formula: RVR
(mmHg mL 1 min 1) = MAP (mmHg)/RBF (mL/min). At the
end of the experimental protocol, blood collection was per-
formed by puncturing the abdominal aorta.
Oxidative stress studies
Urinary peroxides were determined by the ferrous
oxidation of xylenol orange version 2 (FOX-2) method.
Ferrous iron is oxidized to ferric iron by peroxides con-
tained in the samples. Xylenol orange reagent shows a
high selectivity for the Fe3+ ion, producing a bluish-purple
complex whose absorbance can be measured at 560 nm
(A = 4.3 104 M/cm). Aliquots (200 ml) of plasma were
mixed with 1.8 mL of xylenol orange reagent. The data
were corrected for gram urinary creatinine and are
reported as nmol/g (18). The lipid peroxidation levels of
malondialdehyde were determined by methods measuring
thiobarbituric acid-reactive substances (TBARS). For the
quantification, 0.4 mL of urine sample with 0.6 mL water
was added to a reaction mixture consisting of 1.0 mL
17.5% trichloroacetic acid (TCA) and 1.0 mL 0.6%
thiobarbituric acid. This mixture was heated in a water
bath at 95°C for 20 min, the solution was removed from
the water bath and cooled on ice, followed by the addition
of 1.0 mL 70% TCA. The solution was homogenized and
incubated for 20 min. Finally, the solution was read in a
spectrophotometer at 534 nm (A = 1.56 105 M/cm). The
data are reported as nmol/g creatinine (19).
Immunohistochemistry
The kidneys were dissected along the non-hilar axis
and fixed in 10% phosphate buffered formalin (Erviegas,
Brazil). Kidney sections were fixed with 4% buffered
paraformaldehyde and then embedded in paraffin (Ervie-
gas). Next, 4-mm thick sections were prepared. The kidney
slices were deparaffinized and rehydrated. Endogenous
peroxidase activity was blocked with 5% H2O2 in absolute
methanol for 10 min at room temperature. To expose the
antigens, kidney sections were boiled in a target retrieval
solution [1 mmol/L tris(hydroxymethyl)aminomethane (Tris),
pH 9.0, with 0.5 mM ethylene glycol tetraacetic acid
(EGTA)] for 10 min. Nonspecific binding was prevented
by incubating the sections in phosphate buffered saline
(PBS) containing 1% bovine serum albumin (BSA), 0.05%
saponin, and 0.2% gelatin. Sections were incubated with
primary antibodies against ET-1 (1:200, rabbit anti-rat;
ABCAM, MA, USA) and angiotensin-2 (1: 200, rabbit anti-
rat IgG; Santa Cruz Biotechnology, USA). Protein expres-
sion was measured using a streptavidin peroxidase kit
(Dako, USA). Sections were stained with diaminobenzidine
for antibody detection and then counterstained with hema-
toxylin. Signals in negative control sections were absent.
Digital photomicrographs were taken through a Leica
DM 1000 upright microscope connected to a workstation
computer through the Leica DFC 310 FX, LAS 3.8 Micro-
scope Camera (Leica, Switzerland). Ten photomicro-
graphs along the kidney cortex were taken and the light
brown staining was quantified (LAS software, version 3.8)
and averaged for each rat. The data are reported as
percentage of stained area.
Statistical analysis
Results are reported as a means±SE. Data were
analyzed by one-way analysis of variance (ANOVA) fol-




At the end of the experimental protocol, the hyperten-
sive animals of the experimental groups CTL, CsA, CsA
+BOS had significantly lower weight than the animals
of the respective normotensive groups; the CSA+MAC
group had no difference in weight compared to their
normotensive group (Figure 1A).
In normotensive animals, treatment with cyclosporin
significantly decreased the weight of the animals compared
to the control group. This decrease was not observed in
animals treated concomitantly with CsA and BOS or MAC.
In hypertensive animals, although treatment with CsA
showed a tendency to decrease weight, there was no sig-
nificant difference in the weight of the CsA, CsA+BOS
and CsA+MAC groups compared to the control group
(Figure 1A).
There was an increase in the urinary volume after
the onset of the hyposodic diet in normotensive (basal:
13.1±1.5 and post-diet: 48.0±4.6 mL) and hypertensive
(basal: 12.9±1.8 and post-diet: 36.4±3.2 mL) rats. This
was expected since sodium is the main ion responsible for
the hydroelectrolytic balance in the organism.
In the post-treatment period, there was no significant
difference in urinary volume between experimental groups
in normotensive or hypertensive animals (Figure 1B).
Renal hemodynamics
MAP was analyzed at the end of the experimental
protocol by means of a probe in the femoral artery. The
results are presented in Figure 2.
The MAP of the hypertensive animals was higher
than the normotensive animals, as expected. Treatment
with CsA further increased the MAP in the normotensive
(CTL: 118±5; CsA: 143±9 mmHg) and hypertensive
animals (CTL: 147±4; CsA: 173±5 mmHg) in relation
to the control. Concomitant treatment with cyclosporin
and BOS or MAC decreased MAP in the normotensive
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Figure 1. Quantitative analyses of A, body weight, and B, urine volume in Wistar rats (normotensive) and genetically hypertensive rats
(SHR) in the control group (CTL), in rats receiving cyclosporine-A (CsA) or receiving CsA and treated with bosentan (CsA+BOS)
or macitentan (CsA+MAC) for 15 days. Data are reported as means±SE. The significance level for a null hypothesis was set at
5% (Po0.05). *Po0.05, compared to the CTL group; **Po0.05 compared to the respective normotensive group; ##Po0.05 compared
to the respective CsA normotensive group. ++Po0.05 compared to the respective CsA+BOS normotensive group (ANOVA followed
by the Tukey test or Student’s t-test).
Figure 2. Quantitative analyses of A,medium arterial blood pressure (MAP); B, renal blood flow (RBF), and C, renal vascular resistance
(RVR) in Wistar (normotensive) and genetically hypertensive (SHR) animals in the control group (CTL), rats receiving cyclosporine-A
(CsA) or receiving CsA and treated with bosentan (CsA+BOS) or macitentan (CsA+MAC) for 15 days. Data are reported as
means±SE. The significance level for a null hypothesis was set at 5% (Po0.05). *Po0.05, compared to the CTL group; **Po0.05,
compared to the respective normotensive control group; #Po0.05, compared to the CsA group (ANOVA followed by the Tukey test or
Student’s t-test).
Braz J Med Biol Res | doi: 10.1590/1414-431X20176373
Endothelin-1 antagonists in CsA nephrotoxicity in SHR rats 4/9
(CsA+BOS: 113±10, CsA+MAC: 117±8 mmHg) and
hypertensive (CsA+BOS: 113±7; CsA+MAC: 135±
10 mmHg) animals compared to the cyclosporine-treated
group. However, this effect was only significant in hyper-
tensive animals (Figure 2A).
Figure 2B shows RBF analyzed in normotensive and
hypertensive animals at the end of the experimental pro-
tocol. There was a significant decrease in RBF in hyper-
tensive animals compared to normotensive animals in the
control group.
Both the hypertensive (CTL: 6.9±0.9 vs CsA: 2.5
±0.4 mL/min) and normotensive (CTL: 3.8±0.6 vs CsA:
2.2±0.2 mL/min) animals treated with CsA showed a
decrease in renal blood flow compared to the respective
control animals. However, only in normotensive (Po0.05)
animals, not in hypertensive animals (P=0.05), this decrease
was significant (Figure 2B). Treatment with BOS reversed
the decrease in CsA-induced RBF in normotensive (CsA+
BOS: 6.38±0.6 mL/min) and hypertensive (CsA+BOS:
5.95±0.8 mL/min) animals. MAC treatment showed the
same pattern, increasing RBF in normotensive (CsA+MAC:
4.7±1.1 mL/min, P=0.05) and hypertensive (CsA+MAC:
3.3±0.8 mL/min, P40.05) animals but this result was
not significant.
Figure 2C shows the RVR measured in the renal artery
of hypertensive and normotensive animals. We observed
that RVR was significantly higher in the hypertensive
control group. Treatment with CsA significantly increased
RVR in both normotensive (CTL: 19.3±1.6, CsA: 60.5±
10.9 mmHg mL-1 min-1) and hypertensive animals (CTL:
44.2±10.0; CsA: 79.8±8.4 mmHg mL-1 min-1) and con-
comitant treatment with BOS, but not with MAC, reversed
the increase in RVR induced by CsA.
Renal function
Renal function was assessed by plasma urea and
creatinine (Figure 3). There was a significant increase in
plasma creatinine in animals treated with CsA in the post-
treatment period in normotensive (CTL: 0.54±0.03; CsA:
1.27±0.11 mg/dL) and hypertensive (CTL: 0.79±0.15,
CsA: 1.57±0.07 mg/dL) animals compared to the control
group. Concomitant treatment with BOS or MAC in nor-
motensive (BOS: 1.07±0.07, MAC: 0.92±0.4 mg/dL) or
hypertensive (BOS: 1.17±0.10, MAC: 1.07±0.05 mg/dL)
animals did not alter this pattern. One exception was
CsA+MAC in hypertensive animals where creatinine
was significantly decreased compared to the CsA group.
(Figure 3A).
Figure 3. Quantitative analyses of A, plasmatic creatinine, B, plasmatic urea, and C, sodium excretions in Wistar (normotensive) and
genetically hypertensive (SHR) rats in the control group (CTL), receiving cyclosporine-A (CsA) or receiving CsA and treated with
bosentan (CsA+BOS) or macitentan (CsA+MAC) for 15 days. Data are reported as means±SE. The significance level for a null
hypothesis was set at 5% (Po0.05). *Po0.05, compared to the CTL group; #Po0.05, compared to the CsA group. +Po0.05,
compared to the CsA+BOS group (ANOVA followed by the Tukey test or Student’s t-test).
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Figure 3B shows the plasma urea concentration in the
CsA treated animals and concomitantly treated with BOS
and MAC. Corroborating creatinine results, there was a
significant increase in plasma urea in the CsA treated
animals in comparison to the respective normotensive
(CTL: 28.1±5.1, CsA: 91.0±10.2 mg/dL) and hyperten-
sive (CTL: 28.7±5.1, CsA: 64.4±2.3 mg/dL) control
groups. Concomitant treatment with BOS but not with
MAC significantly decreased plasma urea in normotensive
animals (BOS: 46.8±10.2; MAC: 83.1±3.1 mg/dL) and
hypertensive animals (BOS: 39.6±2.2; MAC: 81.5±
4.5 mg/dL).
Figure 3C shows the sodium concentration in the urine
of normotensive and hypertensive animals. In normoten-
sive animals, the CsA-treated animals and BOS or
MAC concomitantly treated with CsA animals showed
a decreased urinary sodium excretion compared to the
control group, but this effect was only significant in the
CsA+MAC group.
In hypertensive animals, treatment with CsA concomi-
tantly with BOS and MAC decreased urine sodium, but
this effect was not significant (Figure 3C).
Oxidative stress studies
Oxidative stress was analyzed in urine by lipid perox-
idation by urinary peroxides and tiobarbituric reactive
metabolites. The CsA group presented higher rates of
oxidative metabolites, urinary peroxides and TBARS com-
pared to the CTL group in normotensive and hypertensive
rats. Endothelin antagonists BOS and MAC blunted this
effect (Table 1). Although there was a trend, no significant
difference in TBARS was observed in CsA group com-
pared to the CTL group in hypertensive animals.
Immunoblotting
Figure 4A and B show ET-1 and angiotensin II immuno-
staining in the renal cortex of normotensive and hyper-
tensive animals treated with CsA. ET-1 was significantly
lower in the renal cortex of control hypertensive animals
(CTL: 24.9±3.7%) compared to control normotensive
animals (CTL: 49.4±2.3%; Figure 4B). After treatment
with CsA, this pattern changed, and a significant increase
in the labeling for ET-1 occurred in hypertensive (CsA:
43.8±4.3%) but not in normotensive animals (CsA:
31.1±3.7%). Taken together, this result showed that the
production of ET-1 in the renal cortex increased in hyper-
tensive animals after treatment with CsA.
Figure 4C and D show the immunoblotting for angio-
tensin II in the renal cortex of normotensive and con-
trol hypertensive animals and animals treated with CsA.
Angiotensin II was significantly lower in the renal cortex
of hypertensive animals (CTL: 0.11±0.03%) compared
to normotensive animals (CTL: 1.25±0.36%). After treat-
ment with CsA, there was a significant increase in the
immunostaining in normotensive (CsA: 6.9±0.9%) and
hypertensive animals (CsA: 0.9±0.2%).
Discussion
The side effects associated with the prolonged treat-
ment with CsA (nephrotoxicity, hypertension) limit their
use. Alternative treatments such as the use of macitentan
to CsA-induced nephrotoxicity can attenuate the problem.
CsA exhibits a distinct pattern of toxicity characterized by
acute, subacute and chronic toxicity (20).
In this study, renal lesions were observed in rats in
subacute toxicity. This was associated with an increased
serum creatinine and a decrease in glomerular filtration
rate, arteriolar lesions and arterial hypertension. In our
experimental conditions, we observed an increase in MAP
and RVR with a decrease in RBF in hypertensive animals
when compared to normotensive animals. Treatment with
CsA for 15 days caused an increase in MAP and RVR with
a decrease in RBF in both hypertensive and normotensive
animals. The effect of CsA and other immunosuppressive
agents on systemic and renal hemodynamics has been
demonstrated. The vasoconstrictive effect of CsA has
already been well characterized in other studies in the
literature (6,8,21,22). Interestingly, concomitant treatment
with BOS prevented CsA-induced hemodynamic changes






Wistar SHR Wistar SHR
CTL 4.7±3.4 5.3±3.5 0.35±0.14 0.45±0.30
CsA 45.6±0.3* 16.0±3.1 1.48±0.74* 1.10±0.44
CsA+BOS 4.8±2.5# 5.3±2.9# 0.42±0.09# 0.65±0.42
CsA+MAC 3.4±1.3# 2.7±1.5# 0.69±0.20# 0.68±0.08
Data are reported as means±SE. TBARS: thiobarbituric acid-reactive substances;
CsA: cyclosporin-A; BOS: bosentan; MAC: macitentan. * Po0.05 vs CTL.
# Po0.05 vs CsA (ANOVA followed by the Tukey test or Student’s t-test).
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in normotensive animals, but mainly in hypertensive
animals, since BOS not only reversed the effects of CsA
on hypertensive animals, but also brought the values of
MAP, RVR and RBF to values close to normotensive
animals. This result suggests that the effect of ET-1 induced
by CsA was more pronounced in hypertensive animals.
Interestingly, immunohistochemistry for ET-1 corroborates
this effect. In addition, the involvement of ET-1 in immuno-
suppressive-induced nephrotoxicity has been demon-
strated previously with the use of tracrolimus (FK-506) (23).
In this nephrotoxicity model, renal vasoconstriction induced
by FK-506 was also observed.
We observed an increase in ET-1 production in the
renal cortex mainly in hypertensive animals. In normoten-
sive animals, CsA did not induce an increase in ET-1, but
induced a significant increase in angiotensin II, which has
a renal vasoconstricting action and increases MAP. The
involvement of angiotensin II in renal vasoconstriction and
in the decrease of renal function induced by CsA has also
been shown in the literature (7,24).
MAC at the doses used in the present study decreased
MAP and increased RBF in hypertensive animals, where
endothelin-1 production was prominent. A similar pattern
was observed for BOS. Protective effects of novel ET-1
Figure 4. A, Light microscopy of kidney sections immunostained for endothelin-1 (ET-1, 200 ) and (C) angiotensin II (200 ) in control
rats (CTL) and rats receiving cyclosporine-A (CsA). B, Quantitative analyses of kidney sections stained for ET-1 and (D) angiotensin II.
Data are reported as means±SE. The significance level for a null hypothesis was set at 5% (Po0.05). *Po0.05, compared to the CTL
group, and **Po0.05, compared to the respective normotensive group (ANOVA followed by the Tukey test or Student’s t-test). SHR:
genetically hypertensive rats.
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receptor antagonists have been reported in diabetic
nephropathy and renovascular disease in doses similar to
those used in our experimental model (25,26).
In renal function, CsA treatment increased plasma
creatinine and urea in normotensive and hypertensive
animals. Concomitant treatment with BOS and MAC did
not alter creatinine, but BOS significantly decreased urea.
In our experimental conditions, creatinine may be a marker
of renal function less sensitive to the effect of CsA. Per-
haps another renal function marker should be analyzed,
such as insulin clearance, but this still needs to be
determined.
We did not observe alterations in the production of
urine in the animals submitted to our experimental con-
ditions. No difference was observed in the weight of
the animals among the experimental groups at the end
of the protocol, although the hypertensive animals had
significantly lower weight when compared to normotensive
animals. Excretion of sodium in the urine decreased in
the animals after treatment with CsA in the absence or
presence of BOS or MAC, but this effect was only
significant in the group of normotensive animals treated
with CsA and MAC. It is interesting to note that these
results may have undergone variations because of the
hyposodic diet.
The administration of CsA in Wistar and SHR rats
induced reactive oxygen species generation by enhance-
ment of urinary peroxides and TBARS. BOS and MAC
reduced this effect probably by increasing the antioxidant
capacity in the kidney. Several studies have described the
crucial role of reactive oxygen species in drug-induced
nephropathy, including CsA (27,28).
The results of this study suggested the direct partici-
pation of ET-1 in cyclosporine-induced changes in renal
hemodynamics in rats, especially in hypertensive ani-
mals. We used two drugs considered antagonists of
endothelin-1, bosentan-Ro470203, a non-selective antago-
nist of ET-A and ET-B receptors, and the non-specific
endothelin receptor antagonist macitentan. The effects
of ET-1 antagonists were not significantly different
between normotensive and hypertensive animals. How-
ever, at doses used in the present study, bosentan
appeared to be better at reversing hemodynamic changes
and renal function induced by CsA, mainly in hypertensive
animals, but macitentan could be an alternative to prevent
cyclosporine-A toxicity.
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